Tag: Cancer Research Award

Himanshi Yaduvanshi | Onco-Immunology | Best Researcher Award

Published on by World Science Awards

Dr. Himanshi Yaduvanshi | Onco-Immunology | Best Researcher Award

Springer Nature | India

Dr. Himanshi Yaduvanshi is a PhD-trained life sciences researcher with strong expertise in oncology, immunology, and metabolic disorders, specializing in the interplay between glucose and lipid metabolism and cancer progression. Her research contributions span mechanistic studies in melanoma, breast cancer, and colon cancer, with a particular focus on metabolic reprogramming, macrophage phenotypic switching in obesity-linked tumor growth, and therapeutic modulation of cholesterol pathways. She has published several peer-reviewed research articles in respected journals such as Cancer Research, Cancer Metabolism, Molecular Cell Research, and Journal of Biosciences, in addition to contributing to preprints and collaborative manuscripts currently in preparation. Her work is further strengthened by involvement in an Indian patent on a novel anticancer therapeutic combination, demonstrating her commitment to translational innovation. Dr. Yaduvanshi’s technical proficiency encompasses flow cytometry, confocal microscopy, in vivo tumor models, metabolic assays using Seahorse technology, immunophenotyping, molecular cloning, qPCR, immunoblotting, and proteomics workflows. Her research background is distinguished by effective collaboration across multidisciplinary teams at the National Centre for Cell Science (NCCS), where she led experimental design, troubleshooting, and data analysis for complex, multi-lab projects. She has participated in national and international scientific platforms, presenting her work at the International Union of Immunological Societies (IUIS) Conference, CMBC Conference, and Immuno-Oncology Society of India (I-OSI), earning recognition for both poster and oral presentations. Beyond academic research, Dr. Yaduvanshi contributes to scientific communication and industry engagement through her roles as Technical Sales Manager at Bio Bench Solutions and Associate Editor with Springer Nature, where she ensures the quality and integrity of scientific protocols. Her work collectively supports societal impact by advancing understanding of cancer metabolism and informing the development of more effective therapeutic strategies. With a strong record of research excellence, innovation, and interdisciplinary collaboration, Dr. Yaduvanshi continues to contribute meaningfully to global biomedical science.

Profile: ORCID

Featured Publications

  1. Athavale, D., Yaduvanshi, H., Bhati, F. K., Mayengbam, S. S., More, T., Rapole, S., & Bhat, M. K. (2024). Hypercholesterolemia-induced impairment in sorafenib functionality is overcome by avasimibe co-treatment.
  2. Mayengbam, S. S., Singh, A., Yaduvanshi, H., Bhati, F. K., Deshmukh, B., Athavale, D., Ramteke, P. L., & Bhat, M. K. (2023). Correction: Cholesterol reprograms glucose and lipid metabolism to promote proliferation in colon cancer cells. Cancer & Metabolism, 11.
  3. Singh, A., Mayengbam, S. S., Yaduvanshi, H., Wani, M. R., & Bhat, M. K. (2022). Obesity programs macrophages to support cancer progression. Cancer Research, 82.

Lakshmanan Govindan | Cancer Biology | Best Researcher Award

Published on by World Science Awards

Assist. Prof. Dr. Lakshmanan Govindan | Cancer Biology | Best Researcher Award

Sri Lakshmi Narayana Institute of Medical Sciences, India

Dr. Lakshmanan Govindan is an Assistant Professor in the Department of Centre for Advanced Study in Botany at the University of Madras, specializing in pharmacology and plant biotechnology. His academic journey includes a Ph.D. focused on the isolation of bioactive compounds from medicinal plants and their biological activities, with a strong emphasis on anticancer and antidiabetic properties. He has also contributed significantly to the field of nanotechnology, particularly in the biosynthesis of silver nanoparticles and their applications in drug delivery systems. His research extends to plant tissue culture techniques and the biodegradation of textile dyes, aiming to address environmental concerns. Dr. Govindan’s research skills encompass plant molecular biology, cancer cell line studies, and advanced nanomaterial synthesis, positioning him as a prominent figure in his field. His dedication to research excellence has been recognized through several accolades, including the Young Scientist Award at the International Research Awards on Science, Technology, and Management, and the Best Researcher Award from the Environmental Scientists organization. Additionally, he received the Award of Excellence in Research at the National Faculty Award 2022-2023 by the Novel Research Academy, Puducherry, and the Best Administrator and Best Researcher Awards from the Innovative and Advanced Multidisciplinary Research Foundation in 2024. These honors reflect his commitment to advancing scientific knowledge and his active involvement in academic and research communities. In conclusion, Dr. Lakshmanan Govindan’s multifaceted expertise in pharmacology, plant biotechnology, and nanotechnology, coupled with his extensive research experience and recognition, underscores his significant contributions to science and education.

Profile: Sopus | ORCID | Google Scholar | ResearchGate

Featured Publications

Lakshmanan, G., Sathiyaseelan, A., Kalaichelvan, P. T., & Murugesan, K. (2018). Plant-mediated synthesis of silver nanoparticles using fruit extract of Cleome viscosa L.: Assessment of their antibacterial and anticancer activity. Karbala International Journal of Modern Science, 4(1), 61–68.

Al-Hashimi, A. G., Ammar, A. B., Lakshmanan, G., Cacciola, F., & Lakhssassi, N. (2020). Development of a millet starch edible film containing clove essential oil. Foods, 9(2), 184.

Lakshmanan Govindan, M. K., Anbazhagan, S., Altemimi, A. B., & Karthik, … (2020). Efficacy of antimicrobial and larvicidal activities of green synthesized silver nanoparticles using leaf extract of Plumbago auriculata Lam. Plants, 9(1577), 1–13.

Lakshmikanthan, M., Muthu, S., Krishnan, K., Altemimi, A. B., Haider, N. N., … (2024). A comprehensive review on anthocyanin-rich foods: Insights into extraction, medicinal potential, and sustainable applications. Journal of Agriculture and Food Research, 17, 101245.

Rama, P., Vignesh, A., Lakshmanan, G., & Murugesan, K. (2013). In vitro antioxidant activity of Achyranthes aspera Linn. International Journal of Medical and Pharmaceutical Sciences, 3(2), 67–78.

Rama, P., Baldelli, A., Vignesh, A., Altemimi, A. B., Lakshmanan, G., Selvam, R., … (2022). Antimicrobial, antioxidant, and angiogenic bioactive silver nanoparticles produced using Murraya paniculata (L.) Jack leaves. Nanomaterials and Nanotechnology, 12, 18479804211056167.

 

Jan Hendrik Muller | Oncology and Pathology | Best Researcher Award

Published on by World Science Awards

Mr. Jan Hendrik Muller | Oncology and Pathology | Best Researcher Award

University Clinic Hamburg Eppendorf | Germany

Mr. Jan Hendrik Müller is an accomplished researcher in molecular life sciences with a specialization in cancer proteomics and translational medicine. Currently pursuing his Ph.D. at the Institute of Pathology, University Medical Center Hamburg-Eppendorf, he has established himself as a promising scientist with expertise in cutting-edge proteomic technologies such as LC-MS/MS and mass spectrometry. His academic career reflects a strong foundation in molecular biology, proteomics, and life science research, supported by rigorous training at leading German institutions including the University of Hamburg and Leibniz University Hannover. Jan’s research focuses on understanding cancer biology at the proteomic level, with the aim of identifying novel biomarkers and therapeutic targets. Alongside his academic journey, he has contributed as a research assistant in internationally recognized groups, gaining practical experience in experimental oncology, T-cell research, and collaborative scientific projects. His involvement in both laboratory research and medical volunteer work highlights his dedication to bridging science and societal benefit. Beyond technical expertise, Jan brings leadership, adaptability, and teamwork to his professional profile, making him a well-rounded candidate for recognition. His ability to integrate scientific curiosity with practical applications positions him as a researcher with significant potential to impact both academia and medical science in the future.

Professional Profile

Education

Mr. Jan Hendrik Müller has pursued a progressive and rigorous academic journey in the field of life sciences, developing expertise in molecular biology, proteomics, and translational medicine. He began his higher education at Leibniz University Hannover, where he earned his Bachelor of Science (B.Sc.) in Life Science. During his undergraduate years, Jan developed proficiency in molecular biology techniques including PCR, protein isolation, and confocal microscopy. His bachelor’s thesis, titled “The effects of dextran sodium sulfate on the barrier function of epithelial cells,” allowed him to gain experience in cell culture and epithelial biology. Following this, Jan pursued his Master of Science (M.Sc.) in Molecular Life Science at the University of Hamburg, completing his degree with excellent academic standing. His master’s studies were research-oriented, involving advanced training in proteomics under the guidance of Prof. Dr. Hartmut Schlüter. His projects included mass spectrometry analysis of prostate cancer tissue, contributing to translational cancer research. Building upon this foundation, Jan is currently enrolled in a Doctor of Philosophy (Ph.D.) program at the University Medical Center Hamburg-Eppendorf, focusing on cancer proteomics and drug response profiling. His educational background demonstrates consistent excellence, hands-on laboratory expertise, and a strong commitment to advancing biomedical research.

Professional Experience

Mr. Jan Hendrik Müller’s professional experience demonstrates a balanced combination of academic research, laboratory training, and clinical exposure. Early in his career, he trained as a paramedic and served in hospital settings, gaining valuable insights into patient care and surgical assistance, particularly in orthopedic surgeries. These experiences nurtured his sense of responsibility and motivated his transition from clinical service to biomedical research. During his academic career, he worked as a Research Assistant in the laboratory of Prof. Dr. Hartmut Schlüter at the University Medical Center Hamburg-Eppendorf. There, he specialized in proteomic analysis of prostate cancer tissue using LC-MS/MS, gaining expertise in mass spectrometry, sample preparation, and proteomic pathway analysis. He also contributed to collaborative projects on T-cell immunotherapy, including viral transduction and functional assays for CAR-T-cell research. In addition, Jan has managed laboratory responsibilities such as cryobank administration and patient sample handling, demonstrating both technical and organizational skills. His professional development is also marked by active teamwork in multidisciplinary projects and community service in hospital environments. These diverse experiences highlight his ability to integrate clinical relevance with scientific discovery, making him a well-rounded researcher equipped for impactful contributions to cancer biology and translational medicine.

Research Interests

Mr. Jan Hendrik Müller’s research interests lie at the intersection of molecular biology, proteomics, and translational oncology. His primary focus is the proteomic profiling of cancer tissues, particularly prostate cancer, using advanced techniques such as liquid chromatography coupled with mass spectrometry (LC-MS/MS). Through this approach, he seeks to unravel the molecular mechanisms underlying cancer progression and drug responses, with the goal of identifying novel therapeutic targets and biomarkers for early diagnosis. In addition to cancer proteomics, Jan is also interested in immunotherapy research, having gained experience in CAR-T-cell biology, viral transduction methods, and T-cell functional assays. His broader research goals include integrating proteomic data with systems biology to provide holistic insights into cellular pathways affected by novel drug treatments. Beyond oncology, Jan shows interest in the applications of molecular life sciences in personalized medicine, aiming to develop strategies that bridge fundamental research with clinical application. His interdisciplinary approach reflects his commitment to collaborative science, combining expertise in molecular biology, analytical chemistry, and clinical medicine. Ultimately, his research interests highlight a forward-looking vision to contribute meaningfully to cancer research, drug development, and precision medicine.

Research Skills

Over the course of his academic and professional journey, Mr. Jan Hendrik Müller has developed a broad and advanced skill set in experimental life sciences and proteomics. His expertise includes molecular biology techniques such as PCR, protein production, blotting, and electrophoresis, alongside advanced cell culture methods, including the maintenance of various cell lines and epithelial barrier function analysis. He is proficient in high-level proteomic methodologies, particularly LC-MS/MS and mass spectrometry-based proteome analysis, enabling him to study complex biological samples with precision. In the field of immunology, he has acquired skills in isolation, expansion, and viral transduction of T-cells, as well as functional CAR-T-cell assays. Jan also has experience in fluorescence-activated cell sorting (FACS), confocal microscopy, and proteomic pathway analysis, demonstrating technical versatility. Beyond laboratory skills, he is proficient in bioinformatics tools such as ImageJ, Matlab, and LaTeX for data visualization and documentation. His certifications include Good Manufacturing Practices (GMP), further enhancing his competency in clinical-grade research. In addition, Jan has proven skills in teamwork, problem-solving, and communication, strengthened by his volunteer work in medical and community settings. Together, his research skills position him as a highly capable scientist ready to contribute to complex biomedical projects.

Awards and Honors

While still in the early stages of his academic career, Mr. Jan Hendrik Müller has already received recognition for his academic and professional excellence. During his Master of Science program at the University of Hamburg, he achieved excellent grades, including a distinction in several advanced courses. His bachelor’s and master’s theses received commendation for their originality and scientific rigor, particularly in the field of proteomics and epithelial biology. Jan has also been awarded a certificate in Good Manufacturing Practices (GMP), reflecting his adherence to the highest standards of laboratory and clinical research practices. In addition to formal recognition, his contribution to research projects under internationally respected mentors such as Prof. Dr. Hartmut Schlüter has allowed him to build a reputation as a promising scientist in proteomics research. His community service in hospital environments and volunteer platforms further demonstrate his commitment to societal well-being. While he has yet to receive large-scale international honors, his strong research foundation, combined with his growing publication record and academic contributions, suggests a career trajectory that will lead to greater recognition in the global scientific community in the near future.

Publication TOp Notes

  • High-level STING expression in tumour and inflammatory cells is linked to microsatellite instability and favourable tumour parameters in a cohort of over 1,900 colorectal cancer patients — 2025

  • A Tc1- and Th1-T-lymphocyte-rich tumor microenvironment is a hallmark of MSI colorectal cancer — 2025

  • Prognostic Impact and Spatial Interplay of Immune Cells in Urothelial Cancer — 2024

  • Loss of TROP2 and epithelial cell adhesion molecule expression is linked to grade progression in pTa but unrelated to disease outcome in pT2-4 urothelial bladder carcinomas — 2024

  • Automated Prognosis Marker Assessment in Breast Cancers Using BLEACH&STAIN Multiplexed Immunohistochemistry — 2023

Conclusion

In conclusion, Mr. Jan Hendrik Müller exemplifies the qualities of a dedicated and innovative young researcher in the field of molecular life sciences and cancer proteomics. His academic excellence, demonstrated through his bachelor’s, master’s, and ongoing Ph.D. studies, reflects his consistent pursuit of scientific knowledge and translational medicine. His professional experiences, ranging from hospital assistance to advanced cancer proteomic research, reveal a well-rounded individual capable of integrating clinical insights with laboratory discoveries. With expertise in proteomics, immunotherapy, and molecular biology, Jan has built a diverse skill set that positions him as a valuable contributor to biomedical science. His community involvement, volunteer medical service, and collaborative research engagements highlight his leadership qualities and social responsibility. While there is room for further recognition through expanded publications and global collaborations, his trajectory demonstrates great promise. Jan is not only contributing to cancer research but is also laying the foundation for impactful work in personalized medicine and future healthcare innovation. These achievements, combined with his dedication, make him a deserving candidate for recognition and a strong contender for future leadership in biomedical research.

Daozhen Chen | Oncology | Best Researcher Award

Published on by World Science Awards

Prof. Daozhen Chen | Oncology | Best Researcher Award

Headmaster from Wuxi Higher Health Vocational Technology School, China

Daozhen Chen serves as the Headmaster of Wuxi Higher Health Vocational Technology School and is an esteemed Postdoctoral Fellow in Toxicology. His research is driven by a passion for improving gynecological tumor diagnosis and treatment through advanced, interdisciplinary approaches. His work bridges nanotechnology with innovative therapeutic strategies, including pH-responsive systems, phototherapy, and hyperthermia, providing a multifaceted attack on cancer cells. He has significantly contributed to the development of electrochemiluminescence techniques by integrating metabolomics-derived biomarkers, facilitating early tumor diagnostics. With 141 journal publications indexed in SCI and Scopus, 11 patents, and one book, his academic productivity is remarkable. His research has been applied in numerous consultancy and industry projects, totaling 12 to date. In recognition of his expertise, he holds editorial roles in reputed journals and is actively involved in several professional committees focused on tumor molecular diagnostics and regenerative medicine. His collaborative engagements span multiple national and provincial science funding programs in China. With an impressive citation index of 31 and leadership in 8 major research projects, Dr. Chen exemplifies scholarly dedication. His research outcomes are not only theoretically rich but also hold immense translational potential, making him a strong candidate for the Best Researcher Award.

Professional Profile

Education

Daozhen Chen’s educational foundation is rooted in an advanced and highly specialized domain—Toxicology—where he earned his postdoctoral fellowship. This academic journey has laid the groundwork for his interdisciplinary research, which marries biological science, materials chemistry, and clinical medicine. While specific details of his earlier degrees are not listed, the postdoctoral fellowship itself reflects a high level of academic excellence and specialized training. Postdoctoral work in Toxicology typically involves advanced study in the mechanisms of disease, exposure analysis, and development of therapeutic interventions, all of which are reflected in Dr. Chen’s research output. His educational trajectory has clearly enabled him to explore the intersection of nanotechnology and oncology, and develop new diagnostics and therapeutic strategies. His academic rigor is further evidenced by his publication record and the complexity of the techniques he employs—such as electrochemiluminescence and metabolomics. This educational background supports his leadership roles in academia and professional societies, indicating a solid and broad-based preparation for his research and administrative responsibilities. Dr. Chen’s continued engagement in high-impact research also reflects his commitment to lifelong learning and scientific advancement.

Professional Experience

Daozhen Chen currently serves as the Headmaster at Wuxi Higher Health Vocational Technology School, a role that underscores his leadership capabilities and academic influence. His professional journey is characterized by a dual commitment to administrative excellence and cutting-edge research. As a Postdoctoral Fellow in Toxicology, Dr. Chen has acquired deep insights into the pathophysiology of tumors, particularly gynecological cancers, and has translated this knowledge into practical diagnostic and therapeutic innovations. Over his career, he has led or actively participated in eight major research projects, collaborated on several national and provincial funding initiatives, and played a consultative role in 12 industry-sponsored research projects. Beyond his institutional responsibilities, he serves on the editorial boards of the Clinical Laboratory Journal and China Medical News, reflecting his thought leadership in laboratory medicine. His work has gained recognition across professional circles, evidenced by his participation in high-level committees focusing on tumor molecular diagnostics and regenerative medicine. His experience combines academic inquiry with real-world applications, fostering an environment where scientific discovery and health education go hand in hand. Dr. Chen’s multifaceted professional career affirms his standing as a prominent academic leader in his field.

Research Interests

Dr. Daozhen Chen’s research interests center on tumor immunity, the comprehensive treatment of tumors, and the application of nanomaterials in clinical oncology. His primary focus is the diagnosis and treatment of gynecological tumors, utilizing a multidisciplinary strategy that combines nanotechnology with advanced treatment modalities like pH-responsive systems, phototherapy, and hyperthermia. These strategies aim to improve the efficacy and precision of cancer therapy. Furthermore, his work on the enhancement of electrochemiluminescence methods and the integration of metabolomics-based biomarkers shows a strong interest in early diagnosis technologies. His research is not only theoretical but also highly translational, intended to yield practical outcomes in clinical diagnostics and therapeutics. This application-oriented approach has allowed him to participate in multiple industry and consultancy projects, where he bridges the gap between lab-based innovations and healthcare delivery. Dr. Chen is particularly interested in how nanomaterials can be engineered to respond to specific biochemical environments within the human body, thereby enhancing the selectivity and efficiency of cancer treatments. His diverse research interests converge at the intersection of material science, analytical chemistry, and clinical oncology, highlighting his commitment to interdisciplinary research that directly impacts patient outcomes.

Research Skills

Dr. Daozhen Chen possesses a robust suite of research skills that underpin his high-impact academic and clinical contributions. He is proficient in nanomaterials synthesis and application, particularly for use in tumor-targeting drug delivery systems. His expertise in developing pH-responsive, photothermal, and hyperthermic agents has facilitated the creation of multi-functional therapeutic platforms for cancer treatment. He has also demonstrated technical expertise in electrochemiluminescence methods, advancing their application in clinical diagnostics by incorporating biomarkers identified through metabolomics. Dr. Chen is skilled in metabolomic profiling, which allows for the discovery of disease-specific markers crucial for early diagnosis. His background in toxicology supports his understanding of therapeutic safety and efficacy, while his ability to lead and manage research teams is evident from his role in overseeing eight significant research projects. Furthermore, he is adept at scientific communication, evidenced by his editorial positions and extensive publication record. His interdisciplinary skills extend to regulatory affairs and translational research, ensuring that lab-based discoveries can be effectively adapted to clinical practice. In consultancy projects, he has demonstrated a keen ability to align research outputs with industry needs. Overall, Dr. Chen’s research skills span basic science, technological innovation, and practical application, making him a well-rounded and impactful researcher.

Awards and Honors

Dr. Daozhen Chen’s work has earned him recognition at both national and institutional levels, though specific named awards are not detailed in the application. However, his appointment as Headmaster and multiple roles on national and provincial scientific committees serve as strong indicators of his professional esteem. He holds influential memberships in prestigious organizations such as the Tumor Molecular Diagnosis Expert Committee of the Chinese Society of Integrated Traditional Chinese and Western Medicine and the Stem Cell and Regenerative Medicine Committee, reflecting peer recognition of his subject matter expertise. Additionally, his selection as an editorial board member of two prominent medical journals—Clinical Laboratory Journal and China Medical News—demonstrates trust in his scholarly judgment and academic leadership. His involvement in 12 industry-sponsored projects and 11 patents underlines his success in translating research into tangible innovations. Collectively, these appointments and contributions serve as indirect yet significant honors, recognizing his influence in the fields of oncology, diagnostics, and nanomedicine. While explicit award titles are not listed, the breadth of Dr. Chen’s professional engagement and impact strongly suggests he is held in high regard across academic and clinical circles.

Conclusion

In conclusion, Dr. Daozhen Chen exemplifies the qualities of an outstanding researcher whose work spans groundbreaking innovation, applied science, and institutional leadership. His postdoctoral expertise in toxicology and his commitment to improving gynecological tumor treatment through advanced nanotechnological strategies position him as a pioneer in the field. His research encompasses both diagnostics and therapy, and he has developed novel platforms that merge phototherapy, pH sensitivity, and hyperthermia for more targeted cancer interventions. With 141 scientific publications, 11 patents, and an active role in 12 consultancy projects, Dr. Chen’s academic footprint is both deep and wide. His editorial roles and participation in national expert committees further establish him as a leader in medical research. He combines rigorous scientific inquiry with practical applications, ensuring his findings have a tangible impact on patient care. While there is potential to further enhance the international visibility of his work and secure more globally recognized awards, his credentials already stand as a testament to his excellence. Based on the depth, scope, and impact of his research, Dr. Daozhen Chen is undoubtedly a deserving candidate for the Best Researcher Award. His contributions not only advance academic knowledge but also provide meaningful improvements in medical diagnostics and treatments.

Publications Top Notes

  1. Chitosan oligosaccharide decorated liposomes combined with TH302 for photodynamic therapy in triple negative breast cancer
    Journal: Journal of Nanobiotechnology (2021), 19(1):147
    Authors: Ding Yinan, Yang Rui, Yu Weiping, Tang Qiusha, Chen Daozhen

  2. Expression of Hepcidin and Ferroportin in the Placenta, and Ferritin and Transferrin Receptor 1 Levels in Maternal and Umbilical Cord Blood in Pregnant Women with and without Gestational Diabetes
    Journal: International Journal of Environmental Research and Public Health (2016), 13(8):766
    Authors: Yang Anqiang, Zhao Jun, Lu Minhua, Chen Daozhen, Fu Jinyan

  3. Title: NAD+ Metabolism Reprogramming Drives SIRT1-Dependent Deacetylation Inducing PD-L1 Nuclear Localization in Cervical Cancer
    Journal: Advanced Science, 2025
    Authors: Lu Xinyi, Jin Pingping, Tang Qianyun, Chen Daozhen, Chen Yu

  4. Title: Tumor-specific liquid metal nitric oxide nanogenerator for enhanced breast cancer therapy
    Journal: Asian Journal of Pharmaceutical Sciences, 2025
    Authors: Su Chen, Lin Jianhan, Li Cong, Gu Zhen, Yan Junjie

  5. Title: Glutamine Attenuates Inflammation and Stimulates Amniotic Cell Proliferation in Premature Rupture of Membranes-related in vitro Models
    Journal: Reproductive Sciences, 2025
    Authors: Xiang Xiang, Zhang Linshen, Li Su, Chen Daozhen, Liu Lou

  6. Title: Deciphering ERR family genes as prognostic and immunological biomarkers through pan-cancer analysis with validation in gallbladder cancer
    Journal: Frontiers in Oncology, 2025
    Authors: Gong Wanwan, Wen Sijia, Chen Yu, Zhao Hui, Wang Lei

  7. Title: Lipid metabolism-associated metabolites on cardiovascular diseases: a two-sample Mendelian randomized study
    Journal: Frontiers in Cardiovascular Medicine, 2025
    Authors: Lu Xinyi, Chen Daozhen, Chen Yu

  8. Title: Bile-Liver phenotype: Exploring the microbiota landscape in bile and intratumor of cholangiocarcinoma
    Journal: Computational and Structural Biotechnology Journal, 2025
    Authors: Wang Lei, Zhao Hui, Wu Fan, Chen Yu, Chen Daozhen

  9. Title: Predictive value of vaginal flora analysis in the second trimester for preterm labor
    Journal: Chinese Journal of Microecology, 2024
    Authors: Chen Jiale, Jia Zhen, Chen Yu, Chen Daozhen

  10. Title: Role of the GalNAc-galectin pathway in the healing of premature rupture of membranes
    Journal: Molecular Medicine, 2024
    Authors: Chen Jiale, Liu Lou, Peng Xin Rui, Xu Dexiang, Chen Daozhen

Jasmine Naru | CANCER PROTEOMICS | Women Researcher Award

Published on by World Science Awards

Dr. Jasmine Naru | CANCER PROTEOMICS | Women Researcher Award

Staff Scientist at Fred Hutch Cancer Center, United States

Jasmine Naru is a dedicated biological researcher with a robust background in various biological disciplines, including proteomics, molecular biology, biochemistry, and genetics. She earned her Ph.D. in Biochemistry from Panjab University, India, in 2016, and has since been associated with prestigious research institutions. Currently a Staff Scientist at the Fred Hutchinson Cancer Center in Seattle, WA, Jasmine has contributed significantly to the field of cancer research, particularly focusing on acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Her innovative research approaches aim to enhance risk stratification and therapeutic targeting for these conditions. Jasmine’s work has resulted in multiple publications in high-impact journals, showcasing her expertise and commitment to advancing the understanding of cancer biology.

Professional Profile

Education

Jasmine Naru’s educational journey reflects her commitment to biological research and academic excellence. She completed her Bachelor of Science in Life Sciences with a focus on Zoology, Botany, and Chemistry at Guru Nanak Dev University in 2006. She pursued her Master of Science in Human Genetics, graduating in 2008 from the same institution. Jasmine then advanced her studies at Panjab University, where she earned her Ph.D. in Biochemistry in 2016. Her doctoral research focused on protein profiling in retinoblastoma patients, utilizing mass spectrometry-based proteomics to identify potential biomarkers. This solid educational foundation has equipped her with the necessary knowledge and skills to excel in her research endeavors.

Professional Experience

Jasmine Naru has gained extensive professional experience in the field of biological research. She began her career as a Junior Research Fellow at the Post Graduate Institute of Medical Education and Research (PGIMER) in India in 2010. Her journey continued at Panjab University, where she served as a Junior and Senior Research Fellow until 2016. Following her academic tenure, Jasmine transitioned to the Fred Hutchinson Cancer Center in Seattle as a Postdoctoral Research Fellow, focusing on innovative cancer research projects from 2017 to 2023. Recently, she has taken on the role of Staff Scientist at Fred Hutch, where she develops novel approaches for risk stratification and therapeutic targeting in AML and MDS. Her professional trajectory showcases her dedication to advancing cancer research and her ability to lead impactful projects.

Research Interests

Jasmine Naru’s research interests are centered on advancing the understanding of hematological malignancies, particularly acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). She focuses on the development of innovative strategies for risk stratification and targeted therapy, employing proteomic and genomic approaches to identify novel biomarkers that can enhance patient outcomes. Her work encompasses the use of iPSC-derived cell lines to explore the biology of MDS and the development of immunotherapy techniques for myeloid malignancies. Jasmine is passionate about translating her research findings into clinical applications that can significantly improve the lives of patients facing these challenging diseases, making her a valuable contributor to the field of cancer research.

Research Skills

Jasmine Naru possesses a comprehensive set of research skills that enhance her capabilities as a biological researcher. Her technical proficiency includes advanced techniques in proteomics, such as mass spectrometry (ESI-MS/MS, MALDI-TOF/TOF), as well as quantitative analysis methods like iTRAQ and TMT. Jasmine is adept at using bioinformatics tools for pathway analysis and has experience in various molecular biology techniques, including PCR, ELISA, Western blotting, and flow cytometry. Additionally, she has strong analytical skills, enabling her to interpret complex data effectively. Jasmine’s multitasking abilities and collaborative approach allow her to thrive in fast-paced research environments, making her an asset to any scientific team.

Awards and Honors

Throughout her academic and professional career, Jasmine Naru has received several honors and recognitions for her contributions to the field of biological research. Notably, she was awarded the Junior Research Fellowship from the Indian Council of Medical Education and Research (ICMR) during her early research career, which provided her with essential support to pursue her doctoral studies. Her commitment to excellence is reflected in her successful publication record, with multiple first-author articles in high-impact journals. Jasmine’s research efforts have also been acknowledged through various project grants, such as the SWOG Impact Award and NIH/NIDDK funding, highlighting her contributions to advancing cancer research and her potential for future impactful work.

Conclusion

Overall, Jasmine Naru is a strong candidate for the Best Researcher Award. Her exceptional research experience in oncology, strong technical skills, and noteworthy publication record make her a highly deserving contender. Expanding her work’s breadth and obtaining more independent funding could further solidify her position as a top researcher in her field. Her dedication and scientific contributions already position her as a standout researcher with a clear impact in the scientific community.

Publication Top Note

  1. Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patients
    • Authors: Pogosova-Agadjanyan, E.L., Hua, X., Othus, M., Meshinchi, S., Stirewalt, D.L.
    • Year: 2023
    • Journal: Biomarker Research
    • Volume: 11
    • Issue: 1
    • Page: 31
    • Citations: 0
  2. Examining the impact of age on the prognostic value of ELN-2017 and ELN-2022 acute myeloid leukemia risk stratifications: a report from the SWOG Cancer Research Network
    • Authors: Termini, C.M., Moseley, A., Othus, M., Meshinchi, S., Stirewalt, D.L.
    • Year: 2023
    • Journal: Haematologica
    • Volume: 108
    • Issue: 11
    • Pages: 3148–3151
    • Citations: 2
  3. Coordinated missplicing of TMEM14C and ABCB7 causes ring sideroblast formation in SF3B1-mutant myelodysplastic syndrome
    • Authors: Clough, C.A., Pangallo, J., Sarchi, M., Bradley, R.K., Doulatov, S.
    • Year: 2022
    • Journal: Blood
    • Volume: 139
    • Issue: 13
    • Pages: 2038–2049
    • Citations: 44
  4. AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: A SWOG report
    • Authors: Pogosova-Agadjanyan, E.L., Moseley, A., Othus, M., Meshinchi, S., Stirewalt, D.L.
    • Year: 2020
    • Journal: Biomarker Research
    • Volume: 8
    • Issue: 1
    • Page: 29
    • Citations: 23